This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Auxilium Prediction: FDA Rejects Crooked Penis Drug

MALVERN, Penn. ( TheStreet) -- Let's discuss crooked penises and the prospects for the FDA approval of a new treatment from Auxilium Pharmaceuticals (AUXL). Regulators are expected to announce their approval decision on the Auxilium drug, known as Xiaflex, on Sept. 6.

My prediction: FDA rejection, but I'm torn with indecision. My conviction level is 5-6 out of 10 -- so not much more than a toss up. The Xiaflex clinical trial data show the treatment takes some bend out of crooked penises and reduces related symptoms. Results were consistent across two phase III studies. The drug is also already FDA approved for a similar disease that freezes fingers in bent positions.

The overall Xiaflex benefit seen in the two phase III trials, however, is modest and relied on a questionable efficacy endpoint and a modified patient analysis to barely reach statistical significance. Any FDA adjustment could render the studies negative. Laser-beam straight penises? Um... no, not with Xiaflex. Side effects? Yes, some substantial including three cases of "penile rupture." You're not the only guy squirming right now. Ladies, sympathy, please. The risk-benefit picture with Xiaflex is murky.

Auxilium shares have lost 3 percent this year and closed Friday at $18.06.

Let's delve deeper into the Xiaflex data.

Crooked penis is a real disease. It's call Peyronie's and is caused by the build up of collagen plaque on one side of the penis. This scar tissue, in turn, causes the penis to bend or curve at an extreme angle. Men with Peyronie's experience pain, embarrassment (naturally) and many have difficult engaging in sex for physical and psychological reasons. Current treatments are relatively ineffective. Surgery is an option for worse cases but outcomes aren't always ideal.

Xiaflex is an enzyme that breaks down the collagen plaques. It's injected directly into the penis. Once the plaque starts to dissolve, manual "modeling" or straightening of the penis is supposed to alleviate the bothersome curvature.

Auxilium conducted two phase III studies of in men with Peyronie's in which Xiaflex injections were compared to sham, placebo injections.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
AUXL $36.47 -0.16%
AAPL $124.43 -1.54%
FB $82.22 -1.18%
GOOG $548.00 -0.73%
TSLA $188.77 -0.94%


DOW 17,776.12 -200.19 -1.11%
S&P 500 2,067.89 -18.35 -0.88%
NASDAQ 4,900.8850 -46.5560 -0.94%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs